Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Pregnancy and cardiovascular agents].

A Grand1

  • 1Service de Cardiologie, Centre hospitalier de Valence.

Annales De Cardiologie Et D'Angeiologie
|December 1, 1992
PubMed
Summary
This summary is machine-generated.

Cardiology medications can often be safely used during pregnancy, but some require caution or avoidance due to potential fetal risks. Careful patient monitoring is crucial for managing maternal and fetal health.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Formation mechanism of glyoxal-DNA adduct, a DNA cross-link precursor.

International journal of biological macromolecules·2017
Same author

Radiation-mediated formation of complex damage to DNA: a chemical aspect overview.

The British journal of radiology·2014
Same author

Representations and practices of prevention in elderly populations: investigating acceptance to participate in and adhesion to an intervention study for the prevention of Alzheimer's disease (ACCEPT study)--the need for a multidisciplinary approach.

The journal of nutrition, health & aging·2012
Same author

*H atom and *OH radical reactions with 5-methylcytosine.

The journal of physical chemistry. A·2007
Same author

Molecular structure of a D-homoandrostanyl steroid derivative: single crystal and powder diffraction analyses.

The journal of physical chemistry. B·2006
Same author

[Consensus statement on severe dementia].

Presse medicale (Paris, France : 1983)·2005
Same journal

[Study of Sleep Apnea Syndrome in Patients with Chronic Heart Failure in the Cardiology Department at Yalgado Ouédraogo teaching hospital in 2024 and 2025].

Annales de cardiologie et d'angeiologie·2026
Same journal

[Impact of knowledge and practices of hygieno-dietetical measures in hypertensive people at the Abidjan cardiology institute].

Annales de cardiologie et d'angeiologie·2026
Same journal

[Correlation between carotid atheroma and DAS28 gamma GT score in rheumatoid arthritis in an African black population].

Annales de cardiologie et d'angeiologie·2026
Same journal

[Dobutamine stress echocardiography: Appropriateness of indications and protocol compliance. A single-centre report].

Annales de cardiologie et d'angeiologie·2026
Same journal

[Post-COVID postural orthostatic tachycardia syndrome: Documentation of a hyperadrenergic phenotype by comprehensive autonomic testing].

Annales de cardiologie et d'angeiologie·2026
Same journal

Urban-rural disparities in hypertension prevalence, screening, and control in South Kivu Province, eastern Democratic Republic of the Congo.

Annales de cardiologie et d'angeiologie·2026
See all related articles

Area of Science:

  • Cardiology
  • Pharmacology
  • Obstetrics

Context:

  • Pregnancy necessitates careful consideration of drug effects on fetal development, especially during the first trimester.
  • Cardiovascular medications present unique challenges for maternal and fetal safety.

Purpose:

  • To review the safety and risks of common cardiology drugs during pregnancy.
  • To guide prescribers in selecting appropriate cardiovascular treatments for pregnant patients.

Summary:

  • Many cardiology drugs, including digitalis, furosemide, certain beta-blockers, verapamil, nifedipine (after the first trimester), quinidine, disopyramide, lignocaine, flecainide, amiodarone, heparins, central antihypertensives, dipyridamole, and aspirin, are generally considered safe.
  • Some drugs like bumetanide, moxonidine, newer beta-blockers, cibenzoline, and ticlopidine should be avoided due to insufficient safety data. Spironolactone, bipyridines, diltiazem, and angiotensin-converting enzyme inhibitors pose risks to the fetus or newborn.

Related Experiment Videos

  • For medications such as propafenone and oral anticoagulants, a risk-benefit analysis comparing maternal disease risks with fetal drug risks is essential.

    • Impact:

    • Informed prescribing practices can minimize adverse maternal and fetal outcomes.
    • Appropriate medication management during pregnancy is vital for patient safety and can mitigate medicolegal risks for healthcare providers.